Skip to main content
Equibles
EVO logo

EVO · Evotec SE

Track EVO — free

Use EVO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.86 -0.04 (-2.11%) At close · Sep 4
Rebalance outlook locked
Market Cap
$661.02M
Shares
355.39M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.86 Open$1.86 Day$1.84–1.86 52W close$1.80–4.15 Avg vol 30d64K Short int51K · 0.0% float · 1.0d Short vol17% Last earningsNov 5, 2026 DataOct 2021–Sep 2026

Raw chart and full-history price indicators begin at the captured split on Oct 20, 2021; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 5, 2026 Scheduled · in 9 wks

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-44.8%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −34%
below
Price vs 50-day avg −13%
below
RSI (14) 40
neutral
MACD trend Positive
52-week position 3%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −7%
trailing
6-month return −23%
trailing
YTD return −40%
this year
Relative strength −38%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Distributing
-26% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.01% of float · ▲ +6.5% MoM · 1.0 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
34 holders — mid 3-yr range
Squeeze score 18
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 55%
annualized · 1-yr
Max drawdown −57%
past year
ATR 3.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−34% Bearish
Price vs 50-day avg
−13% Bearish
RSI (14)
40 Neutral
MACD trend
Positive Bullish
52-week position
3% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Distributing
-26% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.01% of float · ▲ +6.5% MoM · 1.0 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
34 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $2 · 3% Range high $4
vs 200-day avg -34% vs 50-day avg -13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EVO
Evotec SE
this stock
$661.02M -39.6% — — 0.0%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
 $66.37B — — — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $59.75B +18.3% — — 0.1%
GALDY
Galderma Group AG/ADR
 $45.51B -5.8% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $42.67B +16.5% +4.3% 60.0 3.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
34
% held
0.9%
Net QoQ
-4.9M sh
Top holder
DCF Advisers, LLC
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Rising
Shares short
50.7K
Days to cover
1.0d
Change
+3.1K sh
View
Short Volume
Short vol %
17%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
1.8K
Value
$4.0K
As of
Aug 13, 2026
View
Off-Exchange
Off-exchange %
28.6%
Week of
Jul 27, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 13, 2026
This year
17
View
Earnings & Events
Earnings Calls Upcoming
Next call
Nov 5, 2026
Last call
Aug 13, 2026
View
Investor Relations
Upcoming events
1
View

Performance

Raw-price comparisons begin at the captured split on Oct 20, 2021; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
EVO -2.6% -7.0% -23.1% -1.1% -39.6%
SPY +0.1% -0.4% +15.1% +0.4% +12.9%
vs SPY -2.7% -6.6% -38.3% -1.5% -52.6%
Key facts CIK 1412558 CUSIP 30050E105 13F (30d) 25 filings 25 filers Visit website